Literature DB >> 32011908

Interstitial Lung Disease in Relatives of Patients with Pulmonary Fibrosis.

Gary M Hunninghake1,2, Luisa D Quesada-Arias1, Nikkola E Carmichael3, Jose M Martinez Manzano1, Sergio Poli De Frías1, Maura Alvarez Baumgartner1, Lisa DiGianni3, Shannon N Gampala-Sagar4, Dominick A Leone4, Swati Gulati1, Souheil El-Chemaly1, Hilary J Goldberg1, Rachel K Putman1, Hiroto Hatabu2,5, Benjamin A Raby1,4,3, Ivan O Rosas1,6.   

Abstract

Rationale: Although relatives of patients with familial pulmonary fibrosis (FPF) are at an increased risk for interstitial lung disease (ILD), the risk among relatives of sporadic idiopathic pulmonary fibrosis (IPF) is not known.
Objectives: To identify the prevalence of interstitial lung abnormalities (ILA) and ILD among relatives of patients with FPF and sporadic IPF.
Methods: Undiagnosed first-degree relatives of patients with pulmonary fibrosis (PF) consented to participate in a screening study that included the completion of questionnaires, pulmonary function testing, chest computed tomography, a blood sample collection for immunophenotyping, telomere length assessments, and genetic testing.Measurements and Main
Results: Of the 105 relatives in the study, 33 (31%) had ILA, whereas 72 (69%) were either indeterminate or had no ILA. Of the 33 relatives with ILA, 19 (58%) had further evidence for ILD (defined by the combination of imaging findings and pulmonary function testing decrements). There was no evidence in multivariable analyses that the prevalence of either ILA or ILD differed between the 46 relatives with FPF and the 59 relatives with sporadic IPF. Relatives with decrements in either total lung or diffusion capacity had a greater than 9-fold increase in their odds of having ILA (odds ratio, 9.6; 95% confidence interval, 3.1-29.8; P < 0.001).Conclusions: An undiagnosed form of ILD may be present in greater than 1 in 6 older first-degree relatives of patients with PF. First-degree relatives of patients with both familial and sporadic IPF appear to be at similar risk. Our findings suggest that screening for PF in relatives might be warranted.

Entities:  

Keywords:  familial pulmonary fibrosis; idiopathic pulmonary fibrosis; interstitial lung abnormalities; interstitial lung disease; screening

Mesh:

Year:  2020        PMID: 32011908      PMCID: PMC7233344          DOI: 10.1164/rccm.201908-1571OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  37 in total

1.  Genetic Evaluation and Testing of Patients and Families with Idiopathic Pulmonary Fibrosis.

Authors:  Jonathan A Kropski; Lisa R Young; Joy D Cogan; Daphne B Mitchell; Lisa H Lancaster; John A Worrell; Cheryl Markin; Na Liu; Wendi R Mason; Tasha E Fingerlin; David A Schwartz; William E Lawson; Timothy S Blackwell; John A Phillips; James E Loyd
Journal:  Am J Respir Crit Care Med       Date:  2017-06-01       Impact factor: 21.405

2.  Imaging Patterns Are Associated with Interstitial Lung Abnormality Progression and Mortality.

Authors:  Rachel K Putman; Gunnar Gudmundsson; Gisli Thor Axelsson; Tomoyuki Hida; Osamu Honda; Tetsuro Araki; Masahiro Yanagawa; Mizuki Nishino; Ezra R Miller; Gudny Eiriksdottir; Elías F Gudmundsson; Noriyuki Tomiyama; Hiroshi Honda; Ivan O Rosas; George R Washko; Michael H Cho; David A Schwartz; Vilmundur Gudnason; Hiroto Hatabu; Gary M Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2019-07-15       Impact factor: 21.405

3.  Basic models for disease occurrence in epidemiology.

Authors:  W D Flanders; D G Kleinbaum
Journal:  Int J Epidemiol       Date:  1995-02       Impact factor: 7.196

4.  Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state. Predicted values, lower limits of normal, and frequencies of abnormality by smoking history.

Authors:  A Miller; J C Thornton; R Warshaw; H Anderson; A S Teirstein; I J Selikoff
Journal:  Am Rev Respir Dis       Date:  1983-03

5.  Natural history of pulmonary fibrosis in two subjects with the same telomerase mutation.

Authors:  Souheil El-Chemaly; Shira G Ziegler; Rodrigo T Calado; Kirkland A Wilson; Hai Ping Wu; Mary Haughey; Nathan R Peterson; Neal S Young; William A Gahl; Joel Moss; Bernadette R Gochuico
Journal:  Chest       Date:  2010-10-21       Impact factor: 9.410

6.  Identification of early interstitial lung disease in smokers from the COPDGene Study.

Authors:  George R Washko; David A Lynch; Shin Matsuoka; James C Ross; Shigeaki Umeoka; Alejandro Diaz; Frank C Sciurba; Gary M Hunninghake; Raúl San José Estépar; Edwin K Silverman; Ivan O Rosas; Hiroto Hatabu
Journal:  Acad Radiol       Date:  2009-09-24       Impact factor: 3.173

7.  Reference spirometric values using techniques and equipment that meet ATS recommendations.

Authors:  R O Crapo; A H Morris; R M Gardner
Journal:  Am Rev Respir Dis       Date:  1981-06

8.  Association Between Interstitial Lung Abnormalities and All-Cause Mortality.

Authors:  Rachel K Putman; Hiroto Hatabu; Tetsuro Araki; Gunnar Gudmundsson; Wei Gao; Mizuki Nishino; Yuka Okajima; Josée Dupuis; Jeanne C Latourelle; Michael H Cho; Souheil El-Chemaly; Harvey O Coxson; Bartolome R Celli; Isis E Fernandez; Oscar E Zazueta; James C Ross; Rola Harmouche; Raúl San José Estépar; Alejandro A Diaz; Sigurdur Sigurdsson; Elías F Gudmundsson; Gudny Eiríksdottír; Thor Aspelund; Matthew J Budoff; Gregory L Kinney; John E Hokanson; Michelle C Williams; John T Murchison; William MacNee; Udo Hoffmann; Christopher J O'Donnell; Lenore J Launer; Tamara B Harrris; Vilmundur Gudnason; Edwin K Silverman; George T O'Connor; George R Washko; Ivan O Rosas; Gary M Hunninghake
Journal:  JAMA       Date:  2016-02-16       Impact factor: 56.272

9.  Densitometric and local histogram based analysis of computed tomography images in patients with idiopathic pulmonary fibrosis.

Authors:  Samuel Y Ash; Rola Harmouche; Diego Lassala Lopez Vallejo; Julian A Villalba; Kris Ostridge; River Gunville; Carolyn E Come; Jorge Onieva Onieva; James C Ross; Gary M Hunninghake; Souheil Y El-Chemaly; Tracy J Doyle; Pietro Nardelli; Gonzalo V Sanchez-Ferrero; Hilary J Goldberg; Ivan O Rosas; Raul San Jose Estepar; George R Washko
Journal:  Respir Res       Date:  2017-03-07

10.  Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.

Authors:  Martin Kolb; Luca Richeldi; Jürgen Behr; Toby M Maher; Wenbo Tang; Susanne Stowasser; Christoph Hallmann; Roland M du Bois
Journal:  Thorax       Date:  2016-09-26       Impact factor: 9.139

View more
  14 in total

1.  Associations of sleep duration and sleep-wake rhythm with lung parenchymal abnormalities on computed tomography: The MESA study.

Authors:  John S Kim; Hassan S Dashti; Tianyi Huang; Brian E Cade; Anna J Podolanczuk; Daniel J O'Hearn; Eric A Hoffman; Heming Wang; John Blaikley; R Graham Barr; Susan Redline
Journal:  J Sleep Res       Date:  2021-09-09       Impact factor: 5.296

2.  Lung transplantation for idiopathic pulmonary fibrosis enriches for individuals with telomere-mediated disease.

Authors:  Jonathan K Alder; Rachel M Sutton; Carlo J Iasella; Mehdi Nouraie; Ritchie Koshy; Stefanie J Hannan; Ernest G Chan; Xiaoping Chen; Yingze Zhang; Mark Brown; Iulia Popescu; Melinda Veatch; Melissa Saul; Annerose Berndt; Barbara A Methé; Alison Morris; Joseph M Pilewski; Pablo G Sanchez; Matthew R Morrell; Steven D Shapiro; Kathleen O Lindell; Kevin F Gibson; Daniel J Kass; John F McDyer
Journal:  J Heart Lung Transplant       Date:  2021-11-15       Impact factor: 13.569

3.  Pulmonary fibrosis screening: quantifying the psychological impact.

Authors:  Chad A Newton
Journal:  Thorax       Date:  2021-02-23       Impact factor: 9.139

Review 4.  Update in Interstitial Lung Disease 2020.

Authors:  Anna J Podolanczuk; Alyson W Wong; Shigeki Saito; Joseph A Lasky; Christopher J Ryerson; Oliver Eickelberg
Journal:  Am J Respir Crit Care Med       Date:  2021-06-01       Impact factor: 21.405

Review 5.  Clinical Relevance and Management of "Pre-Interstitial Lung Disease".

Authors:  Anna J Podolanczuk; Rachel K Putman
Journal:  Clin Chest Med       Date:  2021-06       Impact factor: 4.967

6.  Psychological impact of genetic and clinical screening for pulmonary fibrosis on asymptomatic first-degree relatives of affected individuals.

Authors:  Nikkola Carmichael; Jose M Martinez Manzano; Luisa D Quesada-Arias; Sergio de Frías Poli; Maura Alvarez Baumgartner; Maria A Planchart Ferretto; Lisa DiGianni; Shannon Gampala-Sagar; Dominick A Leone; Swati Gulati; Souheil Y El-Chemaly; Hilary J Goldberg; Rachel Putman; Hiroto Hatabu; Ivan O Rosas; Gary M Hunninghake; Benjamin A Raby
Journal:  Thorax       Date:  2021-01-22       Impact factor: 9.102

7.  Three Steps to Cure Pulmonary Fibrosis. Step 1: The Runaway Train or Groundhog Day?

Authors:  R Gisli Jenkins
Journal:  Am J Respir Crit Care Med       Date:  2020-05-15       Impact factor: 21.405

Review 8.  Familial Pulmonary Fibrosis: Genetic Features and Clinical Implications.

Authors:  David Zhang; Chad A Newton
Journal:  Chest       Date:  2021-06-26       Impact factor: 9.410

9.  Characteristics and Prevalence of Domestic and Occupational Inhalational Exposures Across Interstitial Lung Diseases.

Authors:  Cathryn T Lee; Ayodeji Adegunsoye; Jonathan H Chung; Iazsmin Bauer Ventura; Renea Jablonski; Steven Montner; Rekha Vij; Stella E Hines; Mary E Strek
Journal:  Chest       Date:  2021-02-20       Impact factor: 10.262

10.  Demystifying pulmonary fibrosis.

Authors:  Gisli Jenkins
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-08-05       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.